Candriam Luxembourg S.C.A. increased its position in Clovis Oncology Inc. (NASDAQ:CLVS) by 46.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 47,000 shares of the biopharmaceutical company’s stock after buying an additional 15,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Clovis Oncology were worth $645,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in the company. Fox Run Management L.L.C. bought a new position in Clovis Oncology during the second quarter worth approximately $154,000. CIBC World Markets Inc. boosted its position in Clovis Oncology by 7.8% in the first quarter. CIBC World Markets Inc. now owns 11,680 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 850 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in Clovis Oncology during the first quarter worth approximately $233,000. Kazazian Asset Management LLC bought a new position in Clovis Oncology during the first quarter worth approximately $282,000. Finally, Bellevue Group AG bought a new position in Clovis Oncology during the first quarter worth approximately $1,008,000. 98.46% of the stock is owned by institutional investors and hedge funds.
Shares of Clovis Oncology Inc. (NASDAQ:CLVS) traded up 10.30% on Monday, reaching $32.44. 6,671,644 shares of the company’s stock traded hands. The firm’s market cap is $1.25 billion. The stock has a 50-day moving average of $29.42 and a 200 day moving average of $18.69. Clovis Oncology Inc. has a 12-month low of $11.57 and a 12-month high of $109.18.
Clovis Oncology (NASDAQ:CLVS) last posted its earnings results on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.13) by $0.06. During the same quarter in the previous year, the business earned ($2.10) earnings per share. On average, equities research analysts expect that Clovis Oncology Inc. will post ($9.25) earnings per share for the current year.
A number of equities analysts have commented on CLVS shares. SunTrust Banks Inc. reissued a “buy” rating and issued a $27.65 price target on shares of Clovis Oncology in a research note on Wednesday, September 14th. Stifel Nicolaus reissued a “buy” rating and issued a $30.00 price target on shares of Clovis Oncology in a research note on Thursday, August 18th. Zacks Investment Research raised shares of Clovis Oncology from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research note on Thursday, August 11th. Credit Suisse Group AG restated a “hold” rating on shares of Clovis Oncology in a report on Tuesday, July 12th. Finally, Piper Jaffray Cos. restated a “hold” rating and issued a $14.00 price objective on shares of Clovis Oncology in a report on Wednesday, June 29th. Seven equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Clovis Oncology has an average rating of “Buy” and a consensus price target of $34.06.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.
Want to see what other hedge funds are holding CLVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Clovis Oncology Inc. (NASDAQ:CLVS).
Receive News & Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.